enVVeno Medical Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference
enVVeno Medical (NASDAQ: NVNO), a company focused on venous disease treatment, has participated in the Virtual Investor 'Top 5 for '25' On-Demand Conference. During the event, CEO Robert Berman presented the top five reasons why investors and industry professionals should monitor the company in 2025. The presentation is now available for viewing online through the conference platform and on the company's website in the Investors section under Events.
enVVeno Medical (NASDAQ: NVNO), un'azienda focalizzata sul trattamento delle malattie venose, ha partecipato alla Conferenza Virtual Investor 'Top 5 for '25' On-Demand. Durante l'evento, il CEO Robert Berman ha presentato i cinque motivi principali per cui investitori e professionisti del settore dovrebbero monitorare l'azienda nel 2025. La presentazione è ora disponibile per la visione online tramite la piattaforma della conferenza e sul sito web dell'azienda nella sezione Investitori sotto Eventi.
enVVeno Medical (NASDAQ: NVNO), una empresa centrada en el tratamiento de enfermedades venosas, ha participado en la Conferencia Virtual Investor 'Top 5 for '25' On-Demand. Durante el evento, el CEO Robert Berman presentó las cinco principales razones por las cuales los inversionistas y profesionales de la industria deberían monitorear a la empresa en 2025. La presentación ya está disponible para su visualización en línea a través de la plataforma de la conferencia y en el sitio web de la empresa en la sección de Inversores bajo Eventos.
enVVeno Medical (NASDAQ: NVNO), 정맥 질환 치료에 중점을 둔 회사가 Virtual Investor 'Top 5 for '25' 온디맨드 컨퍼런스에 참여했습니다. 행사 동안 CEO 로버트 버먼은 투자자와 업계 전문가들이 2025년에 회사를 주목해야 하는 다섯 가지 주요 이유를 발표했습니다. 발표 자료는 이제 컨퍼런스 플랫폼과 회사 웹사이트의 투자자 섹션 이벤트 아래에서 온라인으로 시청할 수 있습니다.
enVVeno Medical (NASDAQ: NVNO), une entreprise axée sur le traitement des maladies veineuses, a participé à la conférence virtuelle 'Top 5 for '25' On-Demand. Lors de l'événement, le PDG Robert Berman a présenté les cinq principales raisons pour lesquelles les investisseurs et les professionnels de l'industrie devraient surveiller l'entreprise en 2025. La présentation est désormais disponible en ligne via la plateforme de la conférence et sur le site web de l'entreprise dans la section Investisseurs sous Événements.
enVVeno Medical (NASDAQ: NVNO), ein Unternehmen, das sich auf die Behandlung von Venenerkrankungen spezialisiert hat, hat an der virtuellen Investorenkonferenz 'Top 5 for '25' On-Demand teilgenommen. Während der Veranstaltung präsentierte CEO Robert Berman die fünf wichtigsten Gründe, warum Investoren und Branchenfachleute das Unternehmen im Jahr 2025 im Auge behalten sollten. Die Präsentation ist jetzt online über die Konferenzplattform und auf der Unternehmenswebsite im Bereich Investoren unter Veranstaltungen verfügbar.
- None.
- None.
On-demand video webcast now available here
IRVINE, CA / ACCESS Newswire / February 19, 2025 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of venous disease, today announced it participated in the Virtual Investor "Top 5 for ‘25" On-Demand Conference.
As part of the event, Robert Berman, Chief Executive Officer of enVVeno, presented the top five reasons of why he believes the investment community and industry colleagues should pay attention to the Company in 2025.
The on-demand video webcast is now accessible for viewing here and on the Events page in the Investors section of the Company's website (envveno.com).
About enVVeno Medical Corporation
enVVeno Medical (NASDAQ:NVNO) is an Irvine, California-based, late clinical-stage medical device Company focused on the advancement of innovative bioprosthetic (tissue-based) solutions to improve the standard of care for the treatment of venous disease. The Company's lead product, the VenoValve®, is a first-in-class surgical replacement venous valve being developed for the treatment of deep venous Chronic Venous Insufficiency (CVI). The Company is also developing a non-surgical, transcatheter based replacement venous valve for the treatment of deep venous CVI called enVVe®. CVI occurs when valves inside of the veins of the leg become damaged, resulting in the backwards flow of blood (reflux), blood pooling in the lower leg, increased pressure in the veins of the leg (venous hypertension) and in severe cases, venous ulcers that are difficult to heal and become chronic. Both the VenoValve and enVVe are designed to act as one-way valves, to help assist in propelling blood up the leg, and back to the heart and lungs. The VenoValve is currently being evaluated in the SAVVE U.S. pivotal study and the Company is currently performing the final testing necessary to seek approval for the pivotal trial for enVVe.
Cautionary Note on Forward-Looking Statements
This press release and any statements of stockholders, directors, employees, representatives and partners of enVVeno Medical Corporation (the "Company") related thereto contain, or may contain, among other things, certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve significant risks and uncertainties. Such statements may include, without limitation, statements identified by words such as "projects," "may," "will," "could," "would," "should," "believes," "expects," "anticipates," "estimates," "intends," "plans," "potential" or similar expressions. These statements are based upon the current beliefs and expectations of the Company's management and are subject to significant risks and uncertainties, including those detailed in the Company's filings with the Securities and Exchange Commission. Actual results and timing (may differ significantly from those set forth or implied in the forward-looking statements. Forward-looking statements involve certain risks and uncertainties that are subject to change based on various factors (many of which are beyond the Company's control). The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future presentations or otherwise, except as required by applicable law.
###
INVESTOR CONTACT:
Jenene Thomas, JTC Team, LLC
NVNO@jtcir.com
(908) 824-0775
SOURCE: enVVeno Medical Corporation
View the original press release on ACCESS Newswire
FAQ
What did enVVeno Medical (NVNO) present at the Virtual Investor Top 5 for '25 Conference?
Where can investors watch enVVeno Medical's (NVNO) Top 5 for '25 presentation?
When did enVVeno Medical (NVNO) participate in the Virtual Investor Conference?
What is enVVeno Medical's (NVNO) primary business focus?
